Moxifloxacina Aurovitas (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacina Aurovitas, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It inhibits bacterial DNA replication and is indicated for several serious bacterial infections in adult patients when the pathogen is known to be susceptible.

GNH USA supplies Moxifloxacina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. The company adheres to EU Good Manufacturing Practice standards and provides reliable logistics for timely delivery.

Moxifloxacin is used to treat bacterial infections affecting the respiratory tract, sinuses, and skin.

- Community‑acquired bacterial pneumonia: effective against susceptible Streptococcus pneumoniae and atypical pathogens. - Acute bacterial sinusitis: eradicates common sinus pathogens such as Haemophilus influenzae. - Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load in COPD flare‑ups. - Skin and skin structure infections: treats Gram‑positive and Gram‑negative organisms in cellulitis and abscesses.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo or light‑headedness. - Abdominal pain: cramp‑like discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, often linked to sudden activity. - QT interval prolongation: may predispose to cardiac arrhythmias. - Clostridioides difficile infection: severe colitis after gut flora disruption. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

When prescribing moxifloxacin, clinicians should consider several safety measures.

- Renal function assessment: adjust use in patients with impaired clearance. - Tendon monitoring: advise patients to report tendon pain or swelling. - QT prolongation risk: avoid in patients with known cardiac conduction disorders. - Elderly caution: increased susceptibility to adverse events. - Concomitant QT‑prolonging drugs: review medication list for additive risk. - Store at below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Systemic corticosteroids: heightened risk of tendon rupture. - Other QT‑prolonging agents (e.g., quinidine, macrolides): additive cardiac risk. - Antacids containing aluminum or magnesium: reduce oral absorption. - Warfarin: may increase INR and bleeding risk. - Theophylline: elevated plasma concentrations.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal effectiveness. - Diabetes medications: potential alteration of glycemic control. - Sulfonylureas: increased risk of hypoglycemia.